A simple blood test that measures the number of lymphocytes, a type of white blood cell in the body, may predict whether people who have relapsed multiple myeloma are going to respond well to CAR-T ...

A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first myeloma patient with this therapy, resulting in a very good response without ...

CURE sat down with Dr. Surbhi Sidana to discuss this treatment combination. CURE recently sat down for an interview with Dr. Surbhi Sidana, chair of the American Society of Hematology’s Committee on ...

CAR T-cell therapy, also known as Chimeric Antigen Receptor T-cell therapy, is a personalized form of immunotherapy treatment that genetically modifies a patient's immune system to target and destroy ...

The types of active multiple myeloma are categorized by the overproduced immunoglobulin, with IgG being the most common and IgE the rarest and most aggressive. Smoldering multiple myeloma is a ...

Please provide your email address to receive an email when new articles are posted on . Lymphopenia at diagnosis or during follow-up can predict OS among patients with multiple myeloma. Researchers ...

Please provide your email address to receive an email when new articles are posted on . A simple blood test that measures lymphocyte count may accurately predict response to chimeric antigen receptor ...